Huiyu Pharmaceutical(SH:688553) Xin Lang Cai Jing·2025-09-19 06:24Core Insights - On September 19, Huayu Pharmaceutical experienced a decline of 5.06%, with a stock price of 24.41 CNY per share, a trading volume of 146 million CNY, a turnover rate of 1.69%, and a total market capitalization of 10.34 billion CNY [1] Company Overview - Sichuan Huayu Pharmaceutical Co., Ltd. is located at 333 Hanyang Road, Shizhong District, Neijiang City, Sichuan Province, and was established on October 12, 2010, with its listing date on October 26, 2021 [1] - The company's main business involves the research, development, production, and domestic and international sales of drugs in the oncology field and complex injectable drugs [1] - The revenue composition of the main business includes: 97.27% from drug sales, 1.66% from technical services, and 1.07% from other sources [1] Fund Holdings - From the perspective of major fund holdings, one fund under Dacheng Fund has a significant position in Huayu Pharmaceutical [2] - Dacheng Medical Health Stock A (012045) held 431,500 shares in the second quarter, accounting for 4.07% of the fund's net value, ranking as the tenth largest holding [2] - The fund has experienced a floating loss of approximately 560,900 CNY today [2] Fund Performance - Dacheng Medical Health Stock A (012045) was established on September 16, 2021, with a latest scale of 153 million CNY [2] - Year-to-date return is 36.96%, ranking 1224 out of 4222 in its category; the one-year return is 52.07%, ranking 1953 out of 3805; since inception, it has a loss of 22.93% [2] - The fund manager, Yang Ting, has a tenure of 11 years and 89 days, with total assets under management of 1.281 billion CNY, achieving a best return of 77.63% and a worst return of -24.45% during his tenure [2]